TRAF1 Antibody
| Code | Size | Price |
|---|
| NSJ-V7358SAF-100UG | 100 ug | £534.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: Mouse IgG1 kappa
Antibody Clonality: Monoclonal
Antibody Clone: TRAF1/2770
Regulatory Status: RUO
Target Species: Human
Application: Immunohistochemistry- Paraffin Embedded (IHC-P)
Storage:
Store the TRAF1 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Documents
Further Information
Application Details:
Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT
Application Note:
Optimal dilution of the TRAF1 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Description:
This mAb recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Format:
Purified
Formulation:
1 mg/ml in 1X PBS; BSA free, sodium azide free
Immunogen:
A portion of amino acids 73-219 from the human protein was used as the immunogen for the TRAF1 antibody.
Limitation:
This TRAF1 antibody is available for research use only.
Localization:
Cytoplasmic
Purity:
Protein G affinity chromatography
Uniprot #:
Q13077